key: cord-0908339-h4lzeqtq
authors: Farina, Andrea; Uccello, Giuseppe; Spreafico, Marta; Bassanelli, Giorgio; Savonitto, Stefano
title: SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade
date: 2020-04-23
journal: Eur J Intern Med
DOI: 10.1016/j.ejim.2020.04.045
sha: 86153151a3e148dcddfd7a6621b26d7bd84beed2
doc_id: 908339
cord_uid: h4lzeqtq

nan

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus first identified in Wuhan, China, at the end of 2019. Since then it has caused more than 1,700,000 confirmed cases of Coronavirus Disease 2019 (COVID-19) worldwide and almost 110,000 deaths [1] . It is responsible for a respiratory syndrome ranging from mild flu-like symptoms to severe respiratory failure (due to acute respiratory distress syndrome), shock, multiorgan failure and death. [2] . SARS-CoV-2 has been first identified in a bronchoalveolar-lavage fluid collected from patients with pneumonia admitted in a hospital of Wuhan on late December [3] and a real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) of nasopharyngeal swabs is currently used to confirm the clinical diagnosis [4] . From its isolation, SARS-CoV-2 has been detected in the respiratory tract, in feces, conjunctiva and in blood [5, 6] but its localization in other sites has not been reported so far. We reported here the first isolation of SARS-CoV-2 in the pericardial fluid of a patient affected with COVID19 and cardiac tamponade undergoing pericardiocentesis. were performed and all resulted negative. Patient underwent high-resolution lung CT scan showing "ground glass" areas with "crazy paving" pattern in both lungs, especially in the left lung, suggesting COVID19-related interstitial pneumonia. Therapy with lopinavir/ritonavir and hydroxychloroquine was started. Blood samples trend showed increasing inflammatory markers (Creactive protein and fibrinogen), lactic dehydrogenase and D-dimer (Table 1 ); in the light of emerging evidence that suggested a role for low-molecular-weight-heparin (LMWH) to decrease mortality in COVID19 patients with markedly elevated D-dimer, enoxaparin was also started [7] . In the subsequent days, the patient was treated with helmet c-PAP for hypoxic respiratory insufficiency with a favourable clinical response. On March 17, we started antibiotic therapy with ampicillin and ceftriaxone because of a second blood culture showing the presence of Enterococcus Faecalis. After some days, global clinical conditions improved with progressive reduction in inflammatory markers (Table 1) . On March 31, he complained of dyspnoea and chest pain: temperature was 36.5 °C, blood pressure 100/65 mmHg, the pulse 130 beats per minute, the respiratory rate 24 beats per minute and the oxygen saturation 98% while he was breathing room air. An echocardiography was performed and documented severe circumferential pericardial effusion conditioning collapse of the right heart sections. As shown in Table 1 , high sensitivity Troponin-I elevation was minimal. An echo-guided pericardiocentesis from subcostal approach was performed, draining 250 cc of sero-haemorragic fluid; a sample was sent to our laboratory for physico-chemical, cytological, microbiological and molecular analysis. A second nasopharyngeal swab and a blood sample for viral RNA detection were performed. Pericardial drainage was maintained in situ for two days and a total of 400 cc of fluid was aspired. Given the progressive improvement of clinical conditions and laboratory results, patient was discharged on April, 6, in fiduciary isolation. Our patient had a previous nasopharyngeal swab positive for all three target genes and a suggestive lung CT scan; after about three weeks and a full course of antiviral therapy, the second nasopharyngeal swab and viral RNA research in the blood were both negative: this data are in agreement with the bland positivity in the pericardial sample. In our opinion the absence of viral RNA in blood and nasopharyngeal secretions and its presence in pericardial fluid could suggest a persistence site; whether this has pathogenic implications is still unknown.

COVID-19 pathogenesis is still being characterized. Until now, virus has been detected only in sites corresponding to clinical manifestations: respiratory, gastro-intestinal and ocular involvement are well known. However, although cardiac involvement has been described [9], pericardial and myocardial tropism of SARS-COV-2 was only assumed. The present data provide a new piece in

World Heart Organization

China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China

China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19

Anticoagulation treatment is associated with decreased mortality in severe Coronavirus Disease 2019 patients with coagulopathy

Dynamic Change Process of Target Genes by RT-PCR Testing of SARS-Cov-2 During the Course of a Coronavirus Disease

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

Declaration of interests

All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.